四川省医疗保障局近日发布相关通知，从6月1日起，四川将电子耳蜗植入术和人工耳蜗正式纳入基 本医疗保险支付范围。通过集采与支付"双管齐下"，患者单例治疗费用将从20余万元降至3万元左右， 大幅减轻听障患者家庭医疗负担。这是记者5月6日从省医保局获悉的。 此次政策将医疗服务价格项目"电子耳蜗植入术"和直接用于手术的医用耗材"人工耳蜗（含植入 体、言语处理器）"纳入基本医疗保险支付范围，按乙类管理，各地医疗保障行政部门根据当地实际， 合理确定具体的先行自付比例。 适用人群为四川省职工基本医疗保险、城乡居民基本医疗保险参保人经确诊为双侧重度或极重度耳 聋，配戴助听器或借助其他助听装置无法改善听力和言语理解力，且符合人工耳蜗植入手术适应症的患 者。人工耳蜗集采中选产品，按中选价格纳入医保支付范围，医保基金按规定比例支付。非中选产品， 价格不高于同类中选产品最高中选价格的，按实际价格支付；高于同类中选产品最高中选价格的，以该 最高中选价格为支付标准，超出部分患者自付。 人工耳蜗是一种用于帮助重度或极重度听力损失患者恢复听力的电子医疗设备。2024年12月，第五 批国家组织高值医用耗材集中带量采购纳入人工耳蜗、外周血管支架 ...

Core Viewpoint - In 2024, Kailitai (300326) reported a revenue of 985 million yuan, a year-on-year increase of 2.96%, but a net profit attributable to shareholders of -106 million yuan, indicating challenges in profitability amidst ongoing healthcare reforms [1][2]. Group 1: Financial Performance - The company achieved a revenue of 985 million yuan in 2024, reflecting a 2.96% increase compared to the previous year [1]. - The net profit attributable to shareholders was -106 million yuan, indicating a loss [1]. - The sales revenue from vertebroplasty business was 276.18 million yuan, while trauma or spinal orthopedic implants generated 64.49 million yuan, with a slight increase in gross margin [1]. Group 2: Business Segments - The low-temperature radiofrequency (energy platform) business reported sales revenue of 218.74 million yuan, marking a 10.48% increase from the previous year [1]. - The medical device trading business generated sales revenue of 142.59 million yuan [1]. - The disinfection and sterilization services achieved sales revenue of 260.74 million yuan, with a year-on-year increase of 21.88% and stable gross margin [1]. Group 3: R&D and Innovation - The company invested in multiple new product developments, with a total of 45 patents authorized during the reporting period, including 10 invention patents [2]. - Total R&D expenditure was 43.98 million yuan, accounting for 4.47% of the revenue [2]. - The company aims to transition from technology following to technology innovation and leadership in orthopedic medical devices [2]. Group 4: Strategic Investments - The company is pursuing a dual strategy of organic growth and external acquisitions to enhance its competitive position in the orthopedic medical device sector [2]. - Investments were made in Dongzhi Medical, Vertebral Medical Technology (Shanghai) Co., Ltd., and Shanghai Shuo Pu Technology Co., Ltd. to strengthen its focus on the orthopedic field [2]. - The company is leveraging its capital operation advantages to integrate industry resources and build a multi-layered industrial chain layout [2].